1. FDA Approved Antibody-Drug Conjugates (ADCs) By 2023 [Internet]. Biopharma PEG. Available from: https://www.biochempeg.com/article/74.html. Accessed 6 Sept 2023.
2. Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody-drug conjugate, Trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17(7):1494–503.
3. Cilliers C, Menezes B, Nessler I, Linderman J, Thurber GM. Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival. Cancer Res. 2018;78(3):758–68.
4. What Are ADC Linkers: Cleavable vs. Non-Cleavable Linkers. Biopharma PEG [Internet]. 2019. Available from: https://www.biochempeg.com/article/87.html. Accessed 12 May 2021.
5. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63(6):1288–96.